Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy
ConclusionsUsing both screening tools (Neuropad + monofilament) is a cost-effective strategy and the dominant alternative, when compared against using the 10-g monofilament alone. The results would be of special relevance in the early detection of diabetic peripheral neuropathy and to ensure the efficient allocation of resources and, thus, t he sustainability of healthcare systems.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Brain | Diabetes | Economics | Endocrinology | Health Management | Neurology | Peripheral Neuropathy